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Abstract 
The occurrence of high rates of somatic mutations in cancer is believed to correspond to increased frequency of 
neo-epitope formation and tumor immunogenicity. Thus, classification of patients with cancer according to degree a 
somatic hyper-mutational status could be proposed as a predictive biomarker of responsiveness to immunotherapy 
with immune checkpoint inhibitors. Here, we discuss the suitable and reliable tests easily adoptable in clinical practice 
to assess somatic mutational status in patients with advanced cancer.
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Recently, the load of non-synonymous sequence vari-
ants has been significantly associated with clinical ben-
efit from treatment of patients with cancer with immune 
checkpoint inhibitors In particular, cancer types associ-
ated with chronic exposure to external mutagens (i.e. 
ultraviolet radiations for melanoma or carcinogens and 
environmental pollutants for lung cancer) or constitu-
tive impairment in genomic integrity (i.e. defective DNA 
repair mechanisms in a subset of colon cancer) have been 
reported to preferentially respond to immune checkpoint 
inhibitors [1–4]. In these conditions, high frequency of 
mutations seems to determine a higher occurrence of 
neo-epitope formation and, thus, tumor immunogenic-
ity [5]. Therefore, classification of cancer patients accord-
ing to their somatic mutational status could be being 
proposed as a predictive biomarker of responsiveness to 
anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) [4] and 
programmed cell death-1 (PD-1) [3] antibodies.
Although qualitative mutation data on somatic cancer 
samples are still limited, research efforts aim at defin-
ing whether the increased load of the non-synonymous 
sequence variants may follow distinct mutational pat-
terns or rather represent the consequence of the accumu-
lation of mutations in specific pathways [6, 7]. Detection 
of specific mutations associated with the response to 
immunotherapy could pave the way to the develop-
ment of affordable qualitative biomarkers (presence vs. 
absence) compared to threshold-depending quantita-
tive parameters. Mutation frequency can be accurately 
analyzed on tumor tissue samples by next-generation 
sequencing NGS). Unfortunately, this methodology suc-
cessfully used for research purposes (indeed, they are 
now commonly taken into account in vast majority of 
recently-approved clinical trials) remain, too far away 
from the practicality of clinical use due to the technical 
difficulties and necessary expertise usually not available 
in clinical oncology laboratories.
While in the future NGS may cross the threshold of 
clinical application, what can be done in the meanwhile?
The following pressing question arises: does a reliable 
and simple diagnostic test exist ready for use in clini-
cal practice for the assessment of a somatic mutational 
status?
To date, only the selective identification of patients 
carrying tumors with genomic instability is practically 
achievable. The occurrence of alterations impairing the 
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integrity may induce progressive accumulation of genetic 
DNA errors and provide a selective advantage for cancer 
cells during malignant evolution. It has been long known 
that tumors with non-functional DNA mismatch repair 
(MMR) present with a higher tendency to bear DNA 
genomic errors and display a pattern of genomic insta-
bility [8]. An efficient MMR apparatus is indeed required 
for accurate DNA replication during cell proliferation, 
whereas defects result in increased DNA mutation rates. 
Microsatellite instability (MSI) inferred by detection of 
ubiquitous somatic variation in length of microsatellite 
sequences in tumor DNA compared to the correspond-
ing normal DNA [8, 9], is indicative of inactivating altera-
tions in mismatch repair genes in many unrelated tumor 
types. The highest prevalence of MSI has been reported 
in colorectal cancer (ranging from 10 to 15% in spo-
radic and 70 to 90% in hereditary non-polyposis colon 
carcinomas, but rarely seen in rectal cancers). Among 
extra-colonic malignancies, MSI has been described in 
endometrial (accounting for 20–30% of cases), small 
bowel (15–25%), gastric (10–20%), ovarian (8–12%), 
gallbladder (5–8%), prostate (3–8%) cancers as well as in 
melanoma (varying from 2 to 30% in primary tumors and 
20% to up to 70% in metastatic lesions) in Western coun-
tries [10, 11].
Considering recent results about the efficacy of the 
PD-1 inhibitors according to the microsatellite status, the 
response rate in the MMR proficient colorectal cancer 
(CRC) and non-CRC cohorts was overall 1% (1/79), with 
a disease control rate of 13% (10/79) [4, 12–15]. Con-
versely, the MMR deficient CRC and non-CRC cohorts 
presented response rates of 58% (15/26) and 55% (12/22), 
respectively, and disease control rates of 88% (23/26) 
and 77% (17/22) [4, 12–15]. Further studies on immune 
checkpoint inhibitors, as single agents or in combination, 
in expanded cohorts of cancer patients evaluated for MSI 
are ongoing.
Genetic (allelic deletions, as indicated by loss of het-
erozygosis in tumor DNA, and/or gene mutations) or 
epigenetic (functional silencing through promoter hyper-
methylation) inactivation of both alleles of the MMR 
genes leads to MSI at somatic level. The MMR system is 
composed of 6 MMR genes and their encoded proteins 
(MLH1, MSH2, MSH3, MSH6, MLH3, PMS2), though 
inactivation of MLH1 and MSH2 account for over 85% of 
MSI cases [16].
A correlation between presence of MSI and abnormal 
MMR gene expression has been widely reported [17–19], 
strongly suggesting that detection of the MMR proteins 
could represent a surrogate approach for the identifica-
tion of tumors with genetic instability. Immunohisto-
chemistry is usually conducted for the main MMR gene 
products, MLH1 and MSH2, failing thus to ensure full 
coverage of all MSI cases. Combination of microsatellite 
analysis and immune histochemical staining for MMR 
gene products better define the so-called mutator pheno-
type, most prominently associated with increased DNA 
mutation rates. In our experience, data from immuno-
histochemistry using both anti-MLH1 and anti-MSH2 
antibodies revealed absent protein expression in about 
two-thirds of the MSI tumors (either colorectal or endo-
metrial carcinomas) [20–24]. As mentioned above, the 
MSI tumors present a genomic instability at somatic level 
due to nonfunctional DNA mismatch repair. Overall, 
concordance between down-regulation of MLH1/MSH2 
gene expression and microsatellite instability varies from 
68% to more than 80%, with an average of 75% [19, 25, 
26]. One could speculate that lack of complete concord-
ance could be due to various factors: (a) the absence of 
protein expression requires the inactivation of both 
alleles of the MMR genes, but the occurrence of delete-
rious mutations altering MMR gene activity may equally 
affect the functional mechanisms of DNA repair without 
impairing protein expression; (b) additional genes may 
be implicated in defects of replication fidelity (c) staining 
can be heterogeneous throughout tumor samples, and 
scoring may not be readily reproducible, particularly in 
the absence of convincing positive internal control. How-
ever, the sensitivity for detection of defective MMR is 
increased when all four MMR proteins are tested [27].
Collating these findings, it becomes evident that MSI 
might be considered the only reliable marker of replica-
tion errors in human cancers and that a well-conducted 
microsatellite analysis may yield an accurate detection 
of genetic instability. MSI testing by polymerase chain 
reaction (PCR) is considered the gold standard allowing 
the identification of abnormalities even in the setting of 
non-truncating protein mutations. For this purpose, a 
recommended reference panel by the National Cancer 
Institute (Bethesda panel assay) exists and comprises 
two mononucleotide repeats (BAT-25 and BAT-26) 
and three dinucleotide repeats (D5S346, D2S123 and 
D17S250) (Table  1) [28]. Although classification also 
includes the low-frequency MSI group (if only one of 
five markers shows instability), presence of MSI should 
be defined by PCR-based detection of at least two 
unstable (due to deletions or insertions) microsatellite 
markers in tumor DNA compared to normal DNA. In 
Fig. 1, representative examples of microsatellite features 
are shown. In addition to the amplification of the five 
polymorphic microsatellite loci of the Bethesda panel 
assay using 5′ fluorescent labeled primers, according to 
ThermoFisher Scientific (Waltham, MA, USA) guide-
lines, a second PCR-based fluorescent multiplex assay 
which may be reliably used in clinical practice to test 
MSI is actually represented by the MSI Analysis System, 
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Version 1.2 (Promega Corp., Madison, WI, USA), ana-
lyzing seven microsatellite markers (mononucletide 
repeats: BAT-25, BAT-26, NR-21, NR-24, and MONO-
27; pentanucleotide repeats: Penta C and Penta D). In 
both cases, the PCR products are separated by capil-
lary electrophoresis using an automated sequencer (i.e. 
3100 or 3500 Series Genetic Analyzers by ThermoFisher 
Scientific) and the output data analyzed with specific 
software (i.e. GeneMapper Analysis Software by Ther-
moFisher Scientific) to determine MSI status. The PCR-
based multiplex assay is also relatively inexpensive (less 
than 50 euros per patient’s classification) as compared 
to the four-five fold higher costs of developing NGS-
based methodologies. 
While waiting for the application in clinical practice 
of NGS technology, the standardization of screening 
approaches based on unique microsatellite panels will 
improve the classification of genetic instability. This 
might represent an opportunity to select more homoge-
neous subsets of unstable patients with a higher muta-
tional load allowing a more accurate assessment of the 
predictive role of increased mutation rates.
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Gene location Microsatellite 
repeat unit
Oligonucleotide primers Amplicon lenght (bp)
BAT25 4p12 cKIT Mononucleotide Forward TCGCCTCCAAGAATGTAAGT 118–123
Reverse TCTGCATTTTAACTATGGCTC
BAT26 2p16.3–p21 hMSH2 Mononucleotide Forward TGACTACTTTTGACTTCAGCC 109–114
Reverse AACCATTCAACATTTTTAACCC
D2S123 2p16 hMSH2 Dinucleotide Forward AAACAGGATGCCTGCCTTTA 197–227
Reverse GGACTTTCCACCTARGGGAC
D5S346 5q21/22 APC Dinucleotide Forward ACTCACTCTAGTGATAAATCGGG 96–122
Reverse AGCAGATAAGACAGTATTAC-
TAGTT
D17S250 17q11.2–q12 BRCA1 Dinucleotide Forward GGAAGAATCAAATAGACAAT 151–169
Reverse GCTGGCCATATATATATTTAAACC
Fig. 1 Electropherograms exemplifying microsatellite markers in 
normal and tumor DNAs. MSS microsatellite stability; MSI microsatel-
lite instability
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